Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Head-to-Head Comparison of Neuroblastoma Detection by [ 64 Cu]GD2 PET and [ 123 I]MIBG SPECT. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1200/jco.21.00278
10.1200/jco.21.00278 · External reference
10.2214/ajr.181.4.1811115
10.2214/ajr.181.4.1811115 · External reference
Comparison between whole-body magnetic resonance imaging and whole-body metaiodobenzylguanidine scintigraphy in the evaluation of primary tumor and metastases in neuroblastoma
10.1002/pbc.30820 · 2024 · External reference
10.1016/s1470-2045(18)30578-3
10.1016/s1470-2045(18)30578-3 · External reference
10.1007/s40265-015-0399-5
10.1007/s40265-015-0399-5 · External reference
10.1200/jco.20.01892
10.1200/jco.20.01892 · External reference
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial
10.1038/s41591-025-03874-6 · 2025 · External reference
Protocol for assessing GD2 on formalin-fixed paraffin-embedded tissue sections using immunofluorescence staining
10.1016/j.xpro.2024.103199 · 2024 · External reference
A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [64Cu]Cu-NOTA-ch14.18/CHO
10.7150/thno.92481 · 2024 · External reference
10.2967/jnumed.122.264626
10.2967/jnumed.122.264626 · External reference
Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma
10.7150/thno.56736 · 2022 · External reference
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
10.1038/s43018-022-00405-x · 2022 · External reference
Multiple immunofluorescence imaging analysis reveals differential expression of disialogangliosides GD3 and GD2 in neuroblastomas
10.1177/10935266211048733 · 2022 · External reference
10.1007/s00259-010-1545-7
10.1007/s00259-010-1545-7 · External reference
Whole-body MRI in children and adolescents: S1 guideline
10.1055/a-0832-2498 · 2019 · External reference
Low-activity [18F]-somatostatin receptor (SSTR) imaging using [18F]SiTATE on a long axial field-of-view PET/CT scanner
10.1186/s40658-025-00720-z · 2025 · External reference
10.1002/ijc.33044
10.1002/ijc.33044 · External reference
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
10.1016/s1470-2045(24)00202-x · 2024 · External reference
10.1056/nejmoa2210859
10.1056/nejmoa2210859 · External reference
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
10.1007/s00259-017-3829-7 · 2018 · External reference
10.2967/jnumed.112.112334
10.2967/jnumed.112.112334 · External reference
10.2967/jnumed.117.193169
10.2967/jnumed.117.193169 · External reference
10.2967/jnumed.122.264063
10.2967/jnumed.122.264063 · External reference
10.2967/jnumed.125.270987
10.2967/jnumed.125.270987 · External reference
10.2967/jnumed.123.267256
10.2967/jnumed.123.267256 · External reference
10.1038/s41568-023-00576-4
10.1038/s41568-023-00576-4 · External reference
Effect of oral β-Glucan on antibody response to ganglioside vaccine in patients with high-risk neuroblastoma: a phase 2 randomized clinical trial
10.1001/jamaoncol.2022.5999 · 2023 · External reference
GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8
10.1007/s00259-024-07033-w · 2025 · External reference
